Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transitionAntonino Glaviano, Alan Prem Kumar, Hannah Lau et al.|Journal of Hematology & Oncology|2025Cited by 128
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Alexander C. J. van Akkooi, Eve‐Marie Neidhardt et al.|The Lancet Oncology|2025Cited by 10
Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare databaseLaurent Mortier, Philippe Saïag, Astrid Blom et al.|European Journal of Cancer|2024Cited by 8